nach oben

Journal of Clinical Immunology

Erschienen in:

01.05.2010

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

verfasst von: Richard Hughes

Erschienen in: Journal of Clinical Immunology | Sonderheft 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Chronic inflammatory demyelinating polyradiculoneuropathy is a chronic progressive or relapsing and remitting disease with a prevalence of up to 8.9 per 100,000.

Methods

This review discusses possible mechanisms, none of which are proven, and describes the evidence for its treatment.

Results

Cochrane Reviews provide evidence that corticosteroids, intravenous immunoglobulin, and plasma exchange are effective short-term treatments. Attempts to confirm the efficacy of other immunosuppressant agents have not been successful, although they are often used in people whose disease is resistant to the first-line treatments.

Conclusions

More and better trials are needed.

Hughes RAC, Bouche P, Cornblath DR, Evers E, Hadden RD, Hahn A, et al. Joint Task Force of the EFNS and the PNS: European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2005;10:220–8.CrossRef

Koski CL, Baumgarten M, Magder LS, Barohn RJ, Goldstein J, Graves M, et al. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2009;277:1–8.CrossRefPubMed

Laughlin RS, Dyck PJ, Melton III LJ, Leibson C, Ransom J. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology. 2009;73:39–45.CrossRefPubMed

Hughes RA, Allen D, Makowska A, Gregson NA. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2006;11:30–46.CrossRefPubMed

Kim HJ, Jung CG, Jensen MA, Dukala D, Soliven B. Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy. J Immunol. 2008;181:8753–60.PubMed

Yan WX, Archelos JJ, Hartung HP, Pollard JD. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:286–92.CrossRefPubMed

Sanvito L, Makowska A, Mahdi-Rogers M, Hadden RD, Peakman M, Gregson N, et al. Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2009;80:333–8.CrossRefPubMed

Meléndez-Vásquez C, Redford J, Choudhary PP, Gray IA, Maitland P, Gregson NA, et al. Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol. 1997;73:124–34.CrossRefPubMed

Willison HJ. Ganglioside complexes: new autoantibody targets in Guillain-Barré syndromes. Nat Clin Pract Neurol. 2005;1:2–3.CrossRefPubMed

10.

Bosboom WM, Van den Berg LH, Mollee I, Sasker LD, Jansen J, Wokke JH, et al. Sural nerve T-cell receptor Vbeta gene utilization in chronic inflammatory demyelinating polyneuropathy and vasculitic neuropathy. Neurology. 2001;56:74–81.PubMed

11.

Kieseier BC, Tani M, Mahad D, Oka N, Ho T, Woodrofe N, et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain. 2002;125:823–34.CrossRefPubMed

12.

Leppert D, Hughes P, Huber S, Erne B, Grygar C, Said G, et al. Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy. Neurology. 1999;53:62–70.PubMed

13.

Madia F, Frisullo G, Nociti V, Conti A, Luigetti M, Del Grande A, et al. pSTAT1, pSTAT3, and T-bet as markers of disease activity in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2009;14:107–17.CrossRefPubMed

14.

Chi LJ, Wang HB, Wang WZ. Impairment of circulating CD4+CD25+ regulatory T cells in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2008;13:54–63.CrossRefPubMed

15.

Tackenberg B, Jelcic I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A. 2009;106:4788–92.CrossRefPubMed

16.

Mehndiratta MM, Hughes RA: Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. CD002062, 2002.

17.

Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN: Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy [update of Cochrane Database Syst Rev. 2002;(2):CD001797]. Cochrane Database Syst. Rev. CD001797, 2009.

18.

Mehndiratta MM, Hughes RA, Agarwal P: Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. CD003906, 2004.

19.

Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, et al. ICE Study Group: intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7:136–44.CrossRefPubMed

20.

RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol. 2009;8:158–64.CrossRef

21.

Hughes R, Gorson K, Cros D, Griffin J, Pollard J, Vallat J-M, et al.: Efficacy of Interferon Beta-1a in patients with chronic inflammatory demyelinating polyneuropathy. Neurology. 2010;74: 651–7.

22.

Hughes RA, Swan AV, van Doorn PA: Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. CD003280, 2004.

23.

Fialho D, Chan YC, Allen DC, Reilly MM, Hughes RA. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate. J Neurol Neurosurg Psychiatry. 2006;77:544–7.CrossRefPubMed

Titel: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
verfasst von: Richard Hughes
Publikationsdatum: 01.05.2010
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe Sonderheft 1/2010
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-010-9399-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypertonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Abstract

Background

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2010

Natural IgM Antibodies Against Oxidation-Specific Epitopes

Adoptive-Transfer Effects of Intravenous Immunoglobulin in Autoimmunity

Intravenous Immunoglobulin Treatment in Multifocal Motor Neuropathy

Immunomodulatory Therapy to Achieve Maximum Efficacy: Doses, Monitoring, Compliance, and Self-infusion at Home

IVIG Treatment and Prognosis in Guillain–Barré Syndrome

A Novel Role for the IgG Fc Glycan: The Anti-inflammatory Activity of Sialylated IgG Fcs

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin